News | Radiation Therapy | May 04, 2022

PREMIER registry to enroll a minimum of 750 patients and include all solid tumor cancers 

RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas (UT) Southwestern in Dallas.

May 4, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, announced the enrollment of the first patient into its PREMIER registry, a prospective, real-world evidence clinical outcomes registry for patients with all stages of cancer, at the University of Texas (UT) Southwestern in Dallas.  

The PREMIER registry was created to collect data to demonstrate the impact of the RefleXion X1 radiotherapy system, the first-ever system with onboard fast fan-beam KVCT, on patients with all solid tumor and lymphoma cancer types. The registry will expand to include BgRT procedures, a new radiotherapy treatment modality that uses signals detected from positron emission tomography (PET) to guide radiotherapy. The X1 is the first and only system designed with onboard PET detectors. The PREMIER registry will assess health-related quality of life, acute and long-term side effects in patients, and cancer-related outcomes. 

“We believe that adapting radiotherapy plans based on how the tumor responds to the first radiation dose will be a key component in bringing together radiotherapy with drug therapies, such as targeted and immune-oncology agents,” said Tu Dan, M.D., assistant professor in the Department of Radiation Oncology at UT Southwestern Medical Center. “However, to fully understand the utility of this approach, robust and accurate data collected through longitudinal endpoints in prospective registries, such as RefleXion’s PREMIER registry, are imperative.”

The PREMIER registry will include extensive baseline data as well as follow-up data collected at the end of treatment, and then again at three, six, nine, 12, 18 and 24 months. The registry will enroll a minimum of 750 patients from a minimum of four sites throughout the United States.

“Our prospective registry will capture and organize an unprecedented level of data including patient, demographic, tumor, biomarker, imaging and treatment information for all stages of cancer,” said Sean Shirvani, M.D., MPH, chief medical officer at RefleXion. “Our hope is that collecting this rich repository of information before, during, and after treatment will enable our clinical partners to investigate and identify the factors that best determine cancer outcomes, which may then arm patients with the information they need to make better decisions around their care.”

Prospective registries define specific information and characteristics in advance, before data collection or the impacts of a treatment are known, including the check-in interval for patient follow-up. Known as longitudinal data over time, this improves data accuracy because it minimizes the dependency on patient recall. Therefore, prospective registries can draw closer associations between the treatment delivered and a patient’s outcome.

For more information: https://reflexion.com/

Related Content

Feature | Nuclear Imaging

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

May 19, 2022 — Robert L. Bard, M.D., an ITN editorial advisory board member, received one of the highest achievements of ...

Time May 19, 2022
arrow
News | Radiation Therapy

May 18, 2022 — RaySearch announced that the treatment control system RayCommand is in clinical use at the innovative ...

Time May 18, 2022
arrow
Feature | Coronavirus (COVID-19)

Clinical scientists used machine learning (ML) models to explore de-identified electronic health record (EHR) data in ...

Time May 18, 2022
arrow
News | Women's Health

May 18 2022 — Older breast cancer survivors with cardiometabolic risk factors who restricted food intake to eight hours ...

Time May 18, 2022
arrow
News | Radiation Oncology

May 17, 2022 — Radiation oncologists will meet with congressional leaders and staff today to ask for their support of ...

Time May 17, 2022
arrow
Videos | Proton Therapy

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal ...

Time May 16, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
Subscribe Now